H.R. 1613
Referred to CommitteeDrug Price Transparency in Medicaid Act of 2023
Introduced 3/17/2023•118th Congress•House
Latest Action
Referred to the Subcommittee on Health.
3/24/2023 • House
Summary
Drug Price Transparency in Medicaid Act of 2023
This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.
Introduced in House • 3/17/2023
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Business recordsCongressional oversightGovernment information and archivesHealth care costs and insuranceHome and outpatient careInflation and pricesMedicaidPrescription drugsPublic contracts and procurementRetail and wholesale tradesState and local government operationsUser charges and fees
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (38)
Party Breakdown
14
Democrats
24
Republicans
0
Independents
Sponsor
R[
Cosponsors (37)
R[
R[
R[
R[
R[
R[
Bill Journey
Originated in the House
Introduced
March 17, 2023
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Introduced in House3/17/2023